| [1] |
SungH, FerlayJ, SiegelRL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
|
| [2] |
CaoW, ChenHD, YuYW, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J]. Chin Med J (Engl), 2021, 134(7): 783-791.
|
| [3] |
吴春晓, 付晨, 赫捷, 等. 2015年中国结直肠癌发病和死亡情况分析[J]. 中国癌症杂志, 2020, 30(4): 241-245.
|
| [4] |
孙可欣, 郑荣寿, 张思维, 等. 2015年中国分地区恶性肿瘤发病和死亡分析[J]. 中国肿瘤临床, 2019, 28(1): 1-11.
|
| [5] |
郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019, 41(1): 19-28.
|
| [6] |
陈孝平, 汪建平, 赵继宗. 外科学: 第9版[M]. 北京: 人民卫生出版社, 2018.
|
| [7] |
RockCL, DoyleC, Demark-wahnefriedW, et al. Nutrition and physical activity guidelines for cancer survivors[J]. CA Cancer J Clin, 2012, 62(4): 243-274.
|
| [8] |
李鹏, 王拥军, 陈光勇, 等. 中国早期结直肠癌及癌前病变筛查与诊治共识[J]. 中国实用内科杂志, 2015, 35(3): 211-227.
|
| [9] |
DavidsonKW, BarryMJ, MangioneCM, et al. Screening for colorectal cancer: US preventive services task force recommendation statement [J]. JAMA, 2021, 325(19): 1965-1977.
|
| [10] |
李其龙, 马新源, 俞玲玲, 等. 农村高发地区大肠癌优化序贯筛查病变年龄别检出分析[J]. 中华肿瘤杂志, 2013, 35(2): 154-157.
|
| [11] |
中华医学会肿瘤学分会早诊早治学组. 中国结直肠癌早诊早治专家共识[J]. 中华医学杂志, 2020, 100(22): 1691-1698.
|
| [12] |
国家癌症中心中国结直肠癌筛查与早诊早治指南制定专家组. 中国结直肠癌筛查与早诊早治指南(2020,北京)[J]. 中华肿瘤杂志, 2021, 43(1): 16-38.
|
| [13] |
HampelH, FrankelW L, MartinE, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer[J]. J Clin Oncol, 2008, 26(35): 5783-5788.
|
| [14] |
袁瑛, 张苏展, 郑树, 等. 中国人遗传性大肠癌筛检标准的实施方案[J]. 中华肿瘤杂志, 2004, 26(3): 191-192.
|
| [15] |
中国临床肿瘤学会结直肠癌专家委员会,中国抗癌协会大肠癌专业委员会遗传学组,中国医师协会结直肠肿瘤专业委员会遗传专委会. 结直肠癌及其他相关实体瘤微卫星不稳定性检测中国专家共识[J]. 中华肿瘤杂志, 2019, 41(10): 734-741.
|
| [16] |
SieberO M, SegditsasS, KnudsenA L, et al. Disease severity and genetic pathways in attenuated familial adenomatous polyposis vary greatly but depend on the site of the germline mutation[J]. Gut, 2006, 55(10): 1440-1448.
|
| [17] |
YangM, ZhuL, ZhuL, et al. Role of a rare variant in APC gene promoter 1B region in classic familial adenomatous polyposis[J]. Digestion, 2020, 102(4): 1-7.
|
| [18] |
樊代明. 整合肿瘤学•临床卷[M]. 北京: 科学出版社, 2021.
|
| [19] |
樊代明. 整合肿瘤学•基础卷[M]. 西安: 世界图书出版西安有限公司, 2021.
|
| [20] |
TanakaS, KashidaH, SaitoY, et al. Japan Gastroenterological Endoscopy Society guidelines for colorectal endoscopic submucosal dissection/endoscopic mucosal resection[J]. Dig Endosc, 2020, 32(2): 219-239.
|
| [21] |
SaitoY, FukuzawaM, MatsudaT, et al. Clinical outcome of endoscopic submucosal dissection versus endoscopic mucosal resection of large colorectal tumors as determined by curative resection[J]. Surg Endosc, 2010, 24(2): 343-352.
|
| [22] |
中华医学会消化内镜学分会病理学协作组. 中国消化内镜活组织检查与病理学检查规范专家共识(草案)[J]. 中华消化内镜杂志, 2014, 31(9): 481-485.
|
| [23] |
王锡山, 李宗芳, 苏敏. 肿瘤学概论: 第2版[M]. 北京: 人民卫生出版社, 2021.
|
| [24] |
中国NOSES联盟, 中国医师协会结直肠肿瘤专业委员会NOSES专委会. 结直肠肿瘤经自然腔道取标本手术专家共识(2019版)[J/CD]. 中华结直肠疾病电子杂志, 2019, 8(4): 336-342.
|
| [25] |
Beets-tanRGH, LambregtsDMJ, MaasM, et al. Magnetic resonance imaging for clinical management of rectal cancer: Updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting[J]. Eur Radiol, 2018, 28(4): 1465-1475.
|
| [26] |
De JongEA, Ten BergeJC, DwarkasingRS, et al. The accuracy of MRI, endorectal ultrasonography, and computed tomography in predicting the response of locally advanced rectal cancer after preoperative therapy: A metaanalysis[J]. Surgery, 2016, 159(3): 688-699.
|
| [27] |
SauerR, BeckerH, HohenbergerW, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer[J]. N Engl J Med, 2004, 351(17): 1731-1740.
|
| [28] |
SauerR, LierschT, MerkelS, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years[J]. J Clin Oncol, 2012, 30(16): 1926-1933.
|
| [29] |
WagmanR, MinskyBD, CohenAM, et al. Sphincter preservation in rectal cancer with preoperative radiation therapy and coloanal anastomosis: long term follow-up[J]. Int J Radiat Oncol Biol Phys, 1998, 42(1): 51-57.
|
| [30] |
GÉrardJP, ConroyT, BonnetainF, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203[J]. J Clin Oncol, 2006, 24(28): 4620-4625.
|
| [31] |
BOSSETJ F, CALAISG, MINEURL, et al. Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results--EORTC 22921[J]. J Clin Oncol, 2005, 23(24): 5620-5627.
|
| [32] |
BossetJF, ColletteL, CalaisG, et al. Chemotherapy with preoperative radiotherapy in rectal cancer[J]. N Engl J Med, 2006, 355(11): 1114-1123.
|
| [33] |
De CaluwÉL, Van NieuwenhoveY, CeelenWP. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer[J]. Cochrane Database Syst Rev, 2013(2): Cd006041.
|
| [34] |
HofheinzRD, WenzF, PostS, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial[J]. Lancet Oncol, 2012, 13(6): 579-588.
|
| [35] |
中国临床肿瘤学会指南工作委员会. 2020CSCO结直肠癌指南[M]. 北京: 人民卫生出版社, 2020.
|
| [36] |
CercekA, RoxburghCSD, StrombomP, et al. Adoption of total neoadjuvant therapy for locally advanced rectal cancer[J]. JAMA Oncol, 2018, 4(6): e180071.
|
| [37] |
PetrelliF, TrevisanF, CabidduM, et al. Total neoadjuvant therapy in rectal cancer: a systematic review and meta-analysis of treatment outcomes[J]. Ann Surg, 2020, 271(3): 440-448.
|
| [38] |
ZhuJ, LiuA, SunX, et al. Multicenter, randomized, phase III trial of neoadjuvant chemoradiation with capecitabine and irinotecan guided by UGT1A1 status in patients with locally advanced rectal cancer[J]. J Clin Oncol, 2020, 38(36): 4231-4239.
|
| [39] |
Van GijnW, MarijnenCA, NagtegaalID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial[J]. Lancet Oncol, 2011, 12(6): 575-582.
|
| [40] |
BujkoK, NowackiM P, Nasierowska-guttmejerA, et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer[J]. Br J Surg, 2006, 93(10): 1215-1223.
|
| [41] |
NganSY, BurmeisterB, FisherRJ, et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04[J]. J Clin Oncol, 2012, 30(31): 3827-3833.
|
| [42] |
Garcia-aguilarJ, ChowOS, SmithDD, et al. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial[J]. Lancet Oncol, 2015, 16(8): 957-966.
|
| [43] |
FokasE, AllgÄuerM, PolatB, et al. Randomized phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12[J]. J Clin Oncol, 2019, 37(34): 3212-3222.
|
| [44] |
BahadoerRR, DijkstraEA, Van EttenB, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2021, 22(1): 29-42.
|
| [45] |
HuX, LiY Q, LiQG, et al. Adjuvant chemotherapy seemed not to have survival benefit in rectal cancer patients with ypTis-2N0 after preoperative radiotherapy and surgery from a population-based propensity score analysis[J]. Oncologist, 2019, 24(6): 803-811.
|
| [46] |
RothAD, DelorenziM, TejparS, et al. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer[J]. J Natl Cancer Inst, 2012, 104(21): 1635-1646.
|
| [47] |
WellsKO, HawkinsAT, KrishnamurthyDM, et al. Omission of adjuvant chemotherapy is associated with increased mortality in patients with T3N0 colon cancer with inadequate lymph node harvest[J]. Dis Colon Rectum, 2017, 60(1): 15-21.
|
| [48] |
RibicCM, SargentDJ, MooreMJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer[J]. N Engl J Med, 2003, 349(3): 247-257.
|
| [49] |
SargentDJ, MarsoniS, MongesG, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer[J]. J Clin Oncol, 2010, 28(20): 3219-3226.
|
| [50] |
SinicropeFA, FosterNR, ThibodeauSN, et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy[J]. J Natl Cancer Inst, 2011, 103(11): 863-875.
|
| [51] |
TejparS, SaridakiZ, DelorenziM, et al. Microsatellite instability, prognosis and drug sensitivity of stage II and III colorectal cancer: more complexity to the puzzle[J]. J Natl Cancer Inst, 2011, 103(11): 841-844.
|
| [52] |
QuahHM, ChouJF, GonenM, et al. Identification of patients with high-risk stage II colon cancer for adjuvant therapy[J]. Dis Colon Rectum, 2008, 51(5): 503-507.
|
| [53] |
SchmollH J, TaberneroJ, MarounJ, et al. Capecitabine plus oxaliplatin compared with fluorouracil/folinic acid as adjuvant therapy for stage Ⅲ colon cancer: final results of the No16968 randomized controlled phase Ⅲ trial[J]. J Clin Oncol, 2015, 33(32): 3733-3740.
|
| [54] |
AndrÉT, BoniC, NavarroM, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial[J]. J Clin Oncol, 2009, 27(19): 3109-3116.
|
| [55] |
Van CutsemE, LabiancaR, BodokyG, et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3[J]. J Clin Oncol, 2009, 27(19): 3117-3125.
|
| [56] |
AlbertsS R, SargentD J, NairS, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial[J]. JAMA, 2012, 307(13): 1383-1393.
|
| [57] |
AllegraCJ, YothersG, O'connellMJ, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08[J]. J Clin Oncol, 2011, 29(1): 11-16.
|
| [58] |
De GramontA, Van CutsemE, SchmollHJ, et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial[J]. Lancet Oncol, 2012, 13(12): 1225-1233.
|
| [59] |
BiagiJJ, RaphaelMJ, MackillopWJ, et al. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis[J]. JAMA, 2011, 305(22): 2335-2342.
|
| [60] |
National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology, Rectal Cancer, Version 1, 2021. [EB/OL]. (2021-08-12)[2021-09-01].
URL
|
| [61] |
Chinese Watch & Wait Database Research Cooperation Group(CWWD), Chinese Association of Surgeons, Chinese Society of Coloproctology, Chinese Medical Doctor Association, et al. Consensus on the Watch and Wait policy in rectal cancer patients after neoadjuvant treatment (2020 version)[J]. Chin J Gastrointest Surg, 2020, 23(1): 1-9.
|
| [62] |
FernandezLM, SÃo JuliÃoGP, FigueiredoNL, et al. Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait Database: a retrospective, international, multicentre registry study[J]. Lancet Oncol, 2021, 22(1): 43-50.
|
| [63] |
中华人民共和国国家卫生健康委员会. 中国结直肠癌诊疗规范(2020年版)[J]. 中华外科杂志, 2020, 58(8): 561-585.
|
| [64] |
WoJY, AnkerCJ, AshmanJB, et al. Radiation therapy for rectal cancer: executive summary of an ASTRO clinical practice guideline[J]. Pract Radiat Oncol, 2021, 11(1): 13-25.
|
| [65] |
Glynne-jonesR, WyrwiczL, TiretE, et al. Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2017, 28(suppl_4): iv22-iv40.
|
| [66] |
FongY, FortnerJ, SunRL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases[J]. Ann Surg, 1999, 230(3): 309-318; discussion 318-321.
|
| [67] |
AyezN, Van Der StokEP, GrÜnhagenDJ, et al. The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: Clinical risk score as possible discriminator[J]. Eur J Surg Oncol, 2015, 41(7): 859-867.
|
| [68] |
NordlingerB, SorbyeH, GlimeliusB, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial[J]. Lancet Oncol, 2013, 14(12): 1208-1215.
|
| [69] |
BridgewaterJA, PughSA, MaishmanT, et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial[J]. Lancet Oncol, 2020, 21(3): 398-411.
|
| [70] |
Van CutsemE, CervantesA, AdamR, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer[J]. Ann Oncol, 2016, 27(8): 1386-1422.
|
| [71] |
中国医师协会外科医师分会, 中华医学会外科分会胃肠外科学组, 中华医学会外科分会结直肠外科学组, 等. 中国结直肠癌肝转移诊断和综合治疗指南(V2020)[J]. 中华胃肠外科杂志, 2021, 24(1): 1-13.
|
| [72] |
AdamR. Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases[J]. Ann Oncol, 2003, 14 Suppl 2: ii13-16.
|
| [73] |
AloiaT, SebaghM, PlasseM, et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases[J]. J Clin Oncol, 2006, 24(31): 4983-4990.
|
| [74] |
FernandezFG, RitterJ, GoodwinJW, et al. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases[J]. J Am Coll Surg, 2005, 200(6): 845-853.
|
| [75] |
AdamR, BhanguiP, PostonG, et al. Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases?[J]. Ann Surg, 2010, 252(5): 774-787.
|
| [76] |
ColucciG, GebbiaV, PaolettiG, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale[J]. J Clin Oncol, 2005, 23(22): 4866-4875.
|
| [77] |
AlbertsSR, HorvathWL, SternfeldWC, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study[J]. J Clin Oncol, 2005, 23(36): 9243-9249.
|
| [78] |
SouglakosJ, AndroulakisN, SyrigosK, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs. FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)[J]. Br J Cancer, 2006, 94(6): 798-805.
|
| [79] |
YeLC, LiuTS, RenL, et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases[J]. J Clin Oncol, 2013, 31(16): 1931-1938.
|
| [80] |
TangW, RenL, LiuT, et al. Bevacizumab plus mFOLFOX6 versus mFOLFOX6 alone as first-line treatment for RAS mutant unresectable colorectal liver-limited metastases: the BECOME randomized controlled trial[J]. J Clin Oncol, 2020, 38(27): 3175-3184.
|
| [81] |
CremoliniC, LoupakisF, AntoniottiC, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study[J]. Lancet Oncol, 2015, 16(13): 1306-1315.
|
| [82] |
SteinA, AtanackovicD, HildebrandtB, et al. Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer[J]. Br J Cancer, 2015, 113(6): 872-877.
|
| [83] |
MargonisGA, BuettnerS, AndreatosN, et al. Association of BRAF mutations with survival and recurrence in surgically treated patients with metastatic colorectal liver cancer[J]. JAMA Surg, 2018, 153(7): e180996.
|
| [84] |
HaddadR, OgilvieRT, CroitoruM, et al. Microsatellite instability as a prognostic factor in resected colorectal cancer liver metastases[J]. Ann Surg Oncol, 2004, 11(11): 977-982.
|
| [85] |
FaronM, PignonJP, MalkaD, et al. Is primary tumour resection associated with survival improvement in patients with colorectal cancer and unresectable synchronous metastases? A pooled analysis of individual data from four randomised trials[J]. Eur J Cancer, 2015, 51(2): 166-176.
|
| [86] |
TarantinoI, WarschkowR, GÜllerU. Palliative primary tumor resection in patients with metastatic colorectal cancer: for whom and when?[J]. Ann Surg, 2017, 265(4): e59-e60.
|
| [87] |
MoritaniK, KanemitsuY, ShidaD, et al. A randomized controlled trial comparing primary tumour resection plus chemotherapy with chemotherapy alone in incurable stage IV colorectal cancer: JCOG1007 (iPACS study)[J]. Jpn J Clin Oncol, 2020, 50(1): 89-93.
|
| [88] |
HuCY, BaileyCE, YouYN, et al. Time trend analysis of primary tumor resection for stage IV colorectal cancer: less surgery, improved survival[J]. JAMA Surg, 2015, 150(3): 245-251.
|
| [89] |
SagerO, DincoglanF, DemiralS, et al. A concise review of pelvic radiation therapy (RT) for rectal cancer with synchronous liver metastases[J]. Int J Surg Oncol, 2019, 2019: 5239042.
|
| [90] |
TournigandC, AndrÉT, AchilleE, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study[J]. J Clin Oncol, 2004, 22(2): 229-237.
|
| [91] |
SaltzLB, ClarkeS, DÍaz-rubioE, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study[J]. J Clin Oncol, 2008, 26(12): 2013-2019.
|
| [92] |
FalconeA, RicciS, BrunettiI, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest[J]. J Clin Oncol, 2007, 25(13): 1670-1676.
|
| [93] |
HeinemannV, Von WeikersthalLF, DeckerT, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2014, 15(10): 1065-1075.
|
| [94] |
VenookAP, NiedzwieckiD, LenzHJ, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial[J]. JAMA, 2017, 317(23): 2392-2401.
|
| [95] |
CremoliniC, AntoniottiC, RossiniD, et al. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial[J]. Lancet Oncol, 2020, 21(4): 497-507.
|
| [96] |
LeDT, UramJN, WangH, et al. PD-1 blockade in tumors with mismatch-repair deficiency[J]. N Engl J Med, 2015, 372(26): 2509-2520.
|
| [97] |
XuRH, ShenL, LiJ, et al. Expert consensus on maintenance treatment for metastatic colorectal cancer in China[J]. Chin J Cancer, 2016, 35: 13.
|
| [98] |
ChibaudelB, Maindrault-goebelF, LledoG, et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study[J]. J Clin Oncol, 2009, 27(34): 5727-5733.
|
| [99] |
LuoHY, LiYH, WangW, et al. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety[J]. Ann Oncol, 2016, 27(6): 1074-1081.
|
| [100] |
QuiddeJ, Hegewisch-beckerS, GraevenU, et al. Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial[J]. Ann Oncol, 2016, 27(12): 2203-2210.
|
| [101] |
CunninghamD, LangI, MarcuelloE, et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial[J]. Lancet Oncol, 2013, 14(11): 1077-1085.
|
| [102] |
Van CutsemE, DanielewiczI, SaundersMP, et al. Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study[J]. Ann Oncol, 2020, 31(9): 1160-1168.
|
| [103] |
CunninghamD, HumbletY, SienaS, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer[J]. N Engl J Med, 2004, 351(4): 337-345.
|
| [104] |
XuRH, MuroK, MoritaS, et al. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial[J]. Lancet Oncol, 2018, 19(5): 660-671.
|
| [105] |
BennounaJ, SastreJ, ArnoldD, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial[J]. Lancet Oncol, 2013, 14(1): 29-37.
|
| [106] |
Van CutsemE, TaberneroJ, LakomyR, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen[J]. J Clin Oncol, 2012, 30(28): 3499-3506.
|
| [107] |
BennounaJ, HiretS, BertautA, et al. Continuation of bevacizumab vs. cetuximab plus chemotherapy after first progression in KRAS wild-type metastatic colorectal cancer: the UNICANCER PRODIGE18 randomized clinical trial[J]. JAMA Oncol, 2019, 5(1): 83-90.
|
| [108] |
InnocentiF, OuFS, QuX, et al. Mutational analysis of patients with colorectal cancer in CALGB/SWOG 80405 identifies new roles of microsatellite instability and tumor mutational burden for patient outcome[J]. J Clin Oncol, 2019, 37(14): 1217-1227.
|
| [109] |
KopetzS, GuthrieKA, MorrisVK, et al. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406)[J], 2021, 39(4): 285-294.
|
| [110] |
CorcoranRB, AtreyaCE, FalchookGS, et al. Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancer[J]. J Clin Oncol, 2015, 33(34): 4023-4031.
|
| [111] |
CorcoranRB, AndrÉT, AtreyaCE, et al. Combined BRAF, EGFR, and MEK inhibition in patients with BRAF(V600E)-mutant colorectal cancer[J]. Cancer Discov, 2018, 8(4): 428-443.
|
| [112] |
OvermanMJ, LonardiS, WongKYM, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer[J]. J Clin Oncol, 2018, 36(8): 773-779.
|
| [113] |
LeDT, KimTW, Van CutsemE, et al. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164[J]. J Clin Oncol, 2020, 38(1): 11-19.
|
| [114] |
WangF, ZhaoQ, WangYN, et al. Evaluation of POLE and POLD1 mutations as biomarkers for immunotherapy outcomes across multiple cancer types[J]. JAMA Oncol, 2019, 5(10): 1504-1506.
|
| [115] |
LiJ, QinS, XuR, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2015, 16(6): 619-629.
|
| [116] |
LiJ, QinS, XuRH, et al. Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial[J]. JAMA, 2018, 319(24): 2486-2496.
|
| [117] |
XuJ, KimT W, ShenL, et al. Results of a randomized, double-blind, placebo-controlled, phase III trial of trifluridine/tipiracil (TAS-102) monotherapy in asian patients with previously treated metastatic colorectal cancer: the TERRA study[J]. J Clin Oncol, 2018, 36(4): 350-358.
|
| [118] |
Sartore-bianchiA, TrusolinoL, MartinoC, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial[J]. Lancet Oncol, 2016, 17(6): 738-746.
|
| [119] |
Meric-bernstamF, HurwitzH, RaghavKPS, et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study[J]. Lancet Oncol, 2019, 20(4): 518-530.
|
| [120] |
CremoliniC, RossiniD, Dell'aquilaE, et al. Rechallenge for patients with RAS andBRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial[J]. JAMA Oncol, 2019, 5(3): 343-350.
|
| [121] |
CoccoE, ScaltritiM, DrilonA. NTRK fusion-positive cancers and TRK inhibitor therapy[J]. Nat Rev Clin Oncol, 2018, 15(12): 731-747.
|
| [122] |
中国医师协会外科医师分会多学科综合治疗专业委员会, 中国抗癌协会大肠癌专业委员会. 结直肠癌肺转移多学科综合治疗专家共识(2018版)[J]. 中国实用外科杂志, 2018, 38(12): 1325-1338.
|
| [123] |
CeelenWP, FlessnerMF. Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence[J]. Nat Rev Clin Oncol, 2010, 7(2): 108-115.
|
| [124] |
KoppeMJ, BoermanOC, OyenWJ, et al. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies[J]. Ann Surg, 2006, 243(2): 212-222.
|
| [125] |
JayneDG, FookS, LoiC, et al. Peritoneal carcinomatosis from colorectal cancer[J]. Br J Surg, 2002, 89(12): 1545-1550.
|
| [126] |
PassotG, DumontF, GoÉrÉD, et al. Multicentre study of laparoscopic or open assessment of the peritoneal cancer index (BIG-RENAPE)[J]. Br J Surg, 2018, 105(6): 663-667.
|
| [127] |
EliasD, MarianiA, CloutierAS, et al. Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin[J]. Eur J Surg Oncol, 2014, 40(11): 1467-1473.
|
| [128] |
CeelenWP, PÅhlmanL, MahtemeH. Pharmacodynamic aspects of intraperitoneal cytotoxic therapy[J]. Cancer Treat Res, 2007, 134: 195-214.
|
| [129] |
SugarbakerP H. Surgical treatment of peritoneal carcinomatosis: 1988 Du Pont lecture[J]. Can J Surg, 1989, 32(3): 164-170.
|
| [130] |
周黄燕, 袁敏, 闵卫平, 等. 结直肠癌术中植入5-氟尿嘧啶缓释剂的Meta分析[J]. 中国药房, 2017, 28(3): 355-359.
|
| [131] |
陈佳楠, 王征, 张阿龙, 等. 雷替曲塞用于结直肠癌术中腹腔灌注化疗的近期安全性评估[J/CD]. 中华结直肠疾病电子杂志, 2019, 8(3): 241-245.
|
| [132] |
中国医师协会结直肠肿瘤专业委员会腹膜肿瘤专业委员会. 结直肠癌腹膜转移预防和治疗腹腔用药中国专家共识(V 2019)[J/CD]. 中华结直肠疾病电子杂志, 2019, 8(4): 329-335.
|
| [133] |
苏昊, 包满都拉, 张育荣, 等. 洛铂用于结直肠癌术中腹腔灌洗化疗的近期疗效分析[J/CD]. 中华结直肠疾病电子杂志, 2018, 7(2): 125-129.
|
| [134] |
王锡山, 孙力, 崔书中, 等. 中国结直肠癌卵巢转移诊疗专家共识(2020版)[J/OL]. 中华结直肠疾病电子杂志, 2020, 9(2): 13-19.
|
| [135] |
刘正, 许宋锋, 刘恩瑞, 等. 中国结直肠癌骨转移多学科综合治疗专家共识(2020版)[J/OL]. 中华结直肠疾病电子杂志, 2020, 9(3): 217-221.
|
| [136] |
中国医师协会结直肠肿瘤专业委员会. 中国结直肠癌脑转移多学科综合治疗专家共识(2020版)[J]. 中华结直肠疾病电子杂志, 2020, 9(2): 109-114.
|
| [137] |
BOYLEK M, SAGARP M, CHALMERSA G, et al. Surgery for locally recurrent rectal cancer[J]. Dis Colon Rectum, 2005, 48(5): 929-937.
|
| [138] |
MARTÍNEZ-MONGER, NAG S, MARTINE W. 125Iodine brachytherapy for colorectal adenocarcinoma recurrent in the pelvis and paraortics[J]. Int J Radiat Oncol Biol Phys, 1998, 42(3): 545-550.
|
| [139] |
黄立中. 中西医结合肿瘤病学[M]. 北京: 中国中医药出版社, 2020.
|
| [140] |
王笑民. 实用中西医结合肿瘤内科学[M]. 北京: 中国中医药出版社, 2014.
|
| [141] |
周岱翰. 中医肿瘤学[M]. 北京: 中国中医药出版社, 2011.
|
| [142] |
中华医学会外科学分会结直肠外科学组,中华医学会外科学分会营养支持学组,中国医师协会外科医师分会结直肠外科医师委员会. 结直肠癌围手术期营养治疗中国专家共识(2019版)[J]. 中国实用外科杂志, 2019, 39(6): 533-537.
|
| [143] |
GamiB, HarringtonK, BlakeP, et al. How patients manage gastrointestinal symptoms after pelvic radiotherapy[J]. Aliment Pharmacol Ther, 2003, 18(10): 987-994.
|
| [144] |
DowningA, MorrisEJ, RichardsM, et al. Health-related quality of life after colorectal cancer in England: a patient-reported outcomes study of individuals 12 to 36 months after diagnosis[J]. J Clin Oncol, 2015, 33(6): 616-624.
|